What does moderate to severe hepatic steatosis (CAP 289 dB/m, liver stiffness 6.6 kPa, stage F0) indicate?

Moderate to Severe Hepatic Steatosis: Clinical Interpretation

Your CAP value of 289 dB/m indicates moderate hepatic steatosis (fat accumulation in the liver), while your liver stiffness of 6.6 kPa confirms no significant fibrosis (stage F0), meaning your liver architecture remains normal despite the fat accumulation.

Understanding Your Results

CAP Value Interpretation

Your CAP of 289 dB/m falls into the moderate steatosis range 1. According to Korean clinical practice guidelines, the normal CAP range is 156-287 dB/m, and your value just exceeds this threshold 1. More specifically:

• Mild steatosis: 250 dB/m cutoff
• Moderate steatosis: 299 dB/m cutoff
• Severe steatosis: 327 dB/m cutoff 1

Your value of 289 dB/m places you in the moderate steatosis category, indicating approximately 33-66% fat content in your liver parenchyma 1.

Recent expert consensus from 2024 uses 280 dB/m as the threshold to identify presumed metabolic dysfunction-associated steatohepatitis (MASH) when combined with other risk factors 2. Your value exceeds this threshold.

Liver Stiffness Assessment

Your liver stiffness of 6.6 kPa is reassuring and confirms stage F0 (no fibrosis). This is well below the thresholds for concern:

• Significant fibrosis (≥F2): 8-10 kPa
• Advanced fibrosis (≥F3): 10-15 kPa
• Cirrhosis (F4): >15 kPa 2, 3

Clinical Significance

What This Means for Your Health

The presence of moderate steatosis without fibrosis indicates early-stage metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called NAFLD 2. This is the most common chronic liver condition worldwide and is strongly associated with:

• Insulin resistance
• Obesity
• Type 2 diabetes
• Metabolic syndrome
• Dyslipidemia 1

Important Caveat About Your Measurements

A critical consideration: moderate-to-severe steatosis can artificially elevate liver stiffness measurements 4, 5, 6. Research shows that in patients without significant fibrosis (F0-F1), the presence of severe steatosis (≥33% or CAP ≥268-287 dB/m) increases LSM values by approximately 1-1.5 kPa 4, 5, 6.

In your case, your actual liver stiffness might be even lower than 6.6 kPa if corrected for the steatosis effect, further confirming the absence of fibrosis 4, 5, 7.

Prognostic Implications

Current Risk Status

Your prognosis is favorable because you have no fibrosis 8. The key prognostic factor in MASLD is the degree of liver fibrosis, not steatosis alone 3. Patients with F0-F1 fibrosis have significantly lower risks of:

• Liver-related complications
• Hepatic decompensation
• Hepatocellular carcinoma
• Liver-related mortality 2, 3

Interestingly, the presence of steatosis may actually be a favorable marker when fibrosis is absent, as some studies show lower incidence of adverse hepatic events in patients with moderate-to-severe steatosis compared to those without steatosis 8.

What Requires Monitoring

You need surveillance for fibrosis progression, as this is the critical determinant of outcomes. The typical monitoring approach:

• Repeat transient elastography every 1-2 years to detect any increase in liver stiffness
• Monitor metabolic risk factors: weight, glucose control, lipid profile, blood pressure
• Check liver enzymes periodically: AST, ALT, though these may be normal even with steatosis 1

Actionable Management

Immediate Priorities

Lifestyle modification is the cornerstone of treatment at your stage 1, 9:

1. Weight loss of 7-10% if overweight/obese - this can resolve steatosis and prevent progression
2. Dietary modifications: reduce refined carbohydrates, saturated fats, and fructose intake
3. Regular aerobic exercise: 150-200 minutes per week of moderate-intensity activity
4. Address metabolic comorbidities: optimize diabetes control, treat dyslipidemia, manage hypertension

When to Consider Pharmacotherapy

You do NOT currently meet criteria for FDA-approved pharmacotherapy 2. Resmetirom, the only FDA-approved medication for MASH, is indicated specifically for patients with moderate to advanced fibrosis (F2-F3), not for F0 stage 2.

Treatment would only be considered if you develop:

• Liver stiffness 10-15 kPa (indicating F2-F3 fibrosis)
• Clinical evidence of steatohepatitis with inflammation on biopsy
• Progressive fibrosis on serial measurements 2

Screening for Other Causes

Ensure other causes of liver disease are excluded 1:

• Excessive alcohol consumption (>20g/day for women, >30g/day for men)
• Viral hepatitis (hepatitis B and C)
• Autoimmune liver disease
• Hemochromatosis
• Wilson's disease
• Medication-induced liver injury

Key Takeaway

Your moderate steatosis with F0 fibrosis represents early, reversible liver disease that responds well to lifestyle interventions 1, 9. The absence of fibrosis is the most important finding, as it indicates you have not yet developed the structural liver damage that drives adverse outcomes. Focus on metabolic risk factor modification and regular monitoring to prevent progression to fibrotic disease, which would significantly alter your prognosis and treatment options 2, 3.